| Id: | acc3687 |
| Group: | 1sens |
| Protein: | FAK |
| Gene Symbol: | PTK2 |
| Protein Id: | Q05397 |
| Protein Name: | FAK1_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr |
| Site Sequence: | |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | SMMC-7721 |
| Disease Info: | |
| Drug: | TGF-β1 |
| Drug Info: | "TGF-β1 is a cytokine that plays a crucial role in various biological processes such as cell growth, differentiation, and immune regulation." |
| Effect: | modulate |
| Effect Info: | TGF-β1 signaling can regulate key signaling pathways in hepatocellular carcinoma cells by modulating the phosphorylation of Akt and FAK and relying on the cell adhesion mechanism. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 14637150 |
| Sentence Index: | 14637150_0 |
| Sentence: | Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells. |
Sequence & Structure:
MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 3 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Terminated | malignant pleural mesothelioma | ClinicalTrials ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | multiple myeloma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic carcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | thyroid carcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Completed | non-small cell lung carcinoma | ClinicalTrials ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | ovarian serous adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic adenocarcinoma | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Completed | pancreatic adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | Uveal Melanoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic ductal adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Not yet recruiting | colorectal cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Completed | lung cancer | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | meningioma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | female reproductive system neoplasm | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | intracranial meningioma | ClinicalTrials |
| PTK2 | VS-4718 | Focal adhesion kinase 1 inhibitor | 1 | Withdrawn | B-cell acute lymphoblastic leukemia | ClinicalTrials |
| PTK2 | VS-4718 | Focal adhesion kinase 1 inhibitor | 1 | Withdrawn | acute myeloid leukemia | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 1 | Active, not recruiting | endometrioid carcinoma | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 1 | Not yet recruiting | neoplasm | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 1 | Recruiting | neoplasm | ClinicalTrials ClinicalTrials |
| PTK2 | CEP-37440 | Focal adhesion kinase 1 inhibitor | 1 | Completed | neoplasm | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| PTK2-Ser29 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -2.43 | ||||||||
| COAD | |||||||||
| HGSC | 0.863 | ||||||||
| ccRCC | 0.19 | ||||||||
| GBM | 0.396 | ||||||||
| HNSC | 0.598 | ||||||||
| LUAD | 0.118 | ||||||||
| LUSC | 0.436 | ||||||||
| non_ccRCC | 0.958 | ||||||||
| PDAC | -0.426 | ||||||||
| UCEC | -0.703 | ||||||||
| PTK2-Ser390 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.882 | ||||||||
| HGSC | -1.086 | ||||||||
| ccRCC | |||||||||
| GBM | 0.204 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser392 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -0.683 | ||||||||
| ccRCC | |||||||||
| GBM | 0.311 | ||||||||
| HNSC | 0.961 | ||||||||
| LUAD | -1.376 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.788 | ||||||||
| PTK2-Ser568 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | 0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser702 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.863 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.233 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | -1.096 | ||||||||
| UCEC | |||||||||
| PTK2-Ser705 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.692 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.067 | ||||||||
| LUAD | -0.651 | ||||||||
| LUSC | -0.337 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.772 | ||||||||
| UCEC | |||||||||
| PTK2-Ser708 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.97 | ||||||||
| COAD | 0.049 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.154 | ||||||||
| GBM | |||||||||
| HNSC | 0.406 | ||||||||
| LUAD | -0.561 | ||||||||
| LUSC | -0.32 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -1.581 | ||||||||
| UCEC | -0.117 | ||||||||
| PTK2-Ser716 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.009 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.14 | ||||||||
| GBM | 0.356 | ||||||||
| HNSC | 1.419 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.907 | ||||||||
| PTK2-Ser722 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.265 | ||||||||
| HGSC | 2.089 | ||||||||
| ccRCC | |||||||||
| GBM | 0.333 | ||||||||
| HNSC | |||||||||
| LUAD | -0.894 | ||||||||
| LUSC | |||||||||
| non_ccRCC | -0.375 | ||||||||
| PDAC | -0.199 | ||||||||
| UCEC | -0.689 | ||||||||
| PTK2-Ser840 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 1.141 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.13 | ||||||||
| GBM | |||||||||
| HNSC | 0.246 | ||||||||
| LUAD | 0.299 | ||||||||
| LUSC | -0.2 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.659 | ||||||||
| UCEC | -2.014 | ||||||||
| PTK2-Ser843 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.028 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.136 | ||||||||
| GBM | 1.188 | ||||||||
| HNSC | 0.169 | ||||||||
| LUAD | 0.224 | ||||||||
| LUSC | 0.928 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.267 | ||||||||
| UCEC | -2.135 | ||||||||
| PTK2-Ser850 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.344 | ||||||||
| HGSC | |||||||||
| ccRCC | -1.085 | ||||||||
| GBM | |||||||||
| HNSC | -0.475 | ||||||||
| LUAD | 1.216 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser910 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.569 | ||||||||
| COAD | -0.212 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.358 | ||||||||
| GBM | -0.058 | ||||||||
| HNSC | 0.662 | ||||||||
| LUAD | -0.174 | ||||||||
| LUSC | 0.71 | ||||||||
| non_ccRCC | -1.419 | ||||||||
| PDAC | 0.888 | ||||||||
| UCEC | -1.609 | ||||||||
| PTK2-Thr394 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.36 | ||||||||
| HGSC | -1.442 | ||||||||
| ccRCC | |||||||||
| GBM | 0.277 | ||||||||
| HNSC | 0.237 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 1.288 | ||||||||
| PTK2-Thr575 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -1.145 | ||||||||
| ccRCC | 0.703 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.442 | ||||||||
| PTK2-Thr914 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.707 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | -0.707 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Tyr397 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.587 | ||||||||
| HGSC | -1.155 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.567 | ||||||||
| PTK2-Tyr570 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.018 | ||||||||
| COAD | 0.395 | ||||||||
| HGSC | 1.385 | ||||||||
| ccRCC | 0.37 | ||||||||
| GBM | -0.571 | ||||||||
| HNSC | -0.744 | ||||||||
| LUAD | -1.592 | ||||||||
| LUSC | -0.966 | ||||||||
| non_ccRCC | 0.897 | ||||||||
| PDAC | 1.49 | ||||||||
| UCEC | -0.646 | ||||||||
| PTK2-Tyr576 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.473 | ||||||||
| HGSC | 1.142 | ||||||||
| ccRCC | |||||||||
| GBM | -0.517 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -1.098 | ||||||||
| PTK2-Tyr577 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 1.045 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.097 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.948 | ||||||||
| PTK2-Tyr720 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.364 | ||||||||
| HGSC | 1.575 | ||||||||
| ccRCC | |||||||||
| GBM | 0.353 | ||||||||
| HNSC | |||||||||
| LUAD | -0.64 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.923 | ||||||||
| PTK2-Tyr861 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.904 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -1.074 | ||||||||
| HNSC | 0.17 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Tyr925 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.981 | ||||||||
| GBM | 0.023 | ||||||||
| HNSC | |||||||||
| LUAD | 0.293 | ||||||||
| LUSC | 0.993 | ||||||||
| non_ccRCC | 0.192 | ||||||||
| PDAC | -1.892 | ||||||||
| UCEC | -0.59 | ||||||||
| PTK2B-Ser361 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.707 | ||||||||
| LUSC | -0.707 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser375 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.873 | ||||||||
| COAD | -0.141 | ||||||||
| HGSC | 2.388 | ||||||||
| ccRCC | -0.73 | ||||||||
| GBM | -0.066 | ||||||||
| HNSC | -0.489 | ||||||||
| LUAD | 0.023 | ||||||||
| LUSC | 0.434 | ||||||||
| non_ccRCC | -0.383 | ||||||||
| PDAC | -1.494 | ||||||||
| UCEC | -0.416 | ||||||||
| PTK2B-Ser571 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | 0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser746 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.625 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.153 | ||||||||
| HNSC | -0.528 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser747 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.707 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser758 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 1.122 | ||||||||
| GBM | -0.326 | ||||||||
| HNSC | -0.796 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser762 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.33 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.021 | ||||||||
| GBM | -0.325 | ||||||||
| HNSC | -0.996 | ||||||||
| LUAD | 1.671 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser778 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.482 | ||||||||
| COAD | -0.158 | ||||||||
| HGSC | 2.376 | ||||||||
| ccRCC | -0.259 | ||||||||
| GBM | -0.528 | ||||||||
| HNSC | -0.202 | ||||||||
| LUAD | -0.526 | ||||||||
| LUSC | 0.229 | ||||||||
| non_ccRCC | 0.124 | ||||||||
| PDAC | -1.539 | ||||||||
| UCEC | |||||||||
| PTK2B-Ser839 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | 1.459 | ||||||||
| ccRCC | -1.431 | ||||||||
| GBM | -0.527 | ||||||||
| HNSC | -0.162 | ||||||||
| LUAD | -0.059 | ||||||||
| LUSC | 0.72 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Thr842 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.307 | ||||||||
| COAD | -0.496 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.037 | ||||||||
| GBM | -1.372 | ||||||||
| HNSC | -0.652 | ||||||||
| LUAD | 1.788 | ||||||||
| LUSC | 0.167 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.067 | ||||||||
| UCEC | -0.713 | ||||||||
| PTK2B-Tyr579 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.707 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.707 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr580 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.707 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.707 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr756 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.248 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.853 | ||||||||
| HNSC | -1.101 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr834 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.605 | ||||||||
| GBM | -1.154 | ||||||||
| HNSC | |||||||||
| LUAD | 0.549 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr849 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | -0.707 |
| HNSC | |
| LUAD | |
| LUSC | 0.707 |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | U | Uterine serous carcinoma | Phosphorylation | 36409196 |
| - | - | U | Cervical cancer/carcinoma | Phosphorylation | 24058594 |
| - | - | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 11287749 |
| - | - | U | Breast cancer | Phosphorylation | 12421874 |
| - | - | U | Head and neck squamous cell carcinoma | Phosphorylation | 22483702 |
| - | - | U | Ovarian cancer | Phosphorylation | 36217544 |
| - | - | U | Cancer | Phosphorylation | 36656716 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | A431 | Imatinib | 8.2423 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | AZD4547 | 7.7576 | - | |
| Q05397 | PTK2 | P | Tyr720 | QATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | AZD4547 | 7.2101 | - | |
| Q05397 | PTK2 | P | Tyr720 | RQATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | AZD4547 | 7.1997 | - | |
| Q05397 | PTK2 | P | Ser574;Thr575;Tyr576;Tyr577 | YMEDS(ph)T(ph)Y(ph)Y(ph)K | PC-9 | AZD4547 | 1.5229 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | Gefitinib | 8.1192 | - | |
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | PC-9 | Gefitinib | 4.9948 | - | |
| Q05397 | PTK2 | P | Tyr720 | RQATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | GeftinibAZD4547-1to80 | 9.855 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | GeftinibAZD4547-1to80 | 8.4574 | - | |
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | PC-9 | GeftinibAZD4547-1to80 | 6.6249 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
